Paroxysmal Atrial Tachycardia Market Research Report- Forecast till 2027

Paroxysmal Atrial Tachycardia Market Information: by Type (AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT)), Diagnosis (ECG, Echocardiogram) Treatment (Calcium Channel Blockers, Digoxin), End User - Forecast till 2027

ID: MRFR/Pharma/3480-HCR | | Region: Global | 110 pages

Paroxysmal Atrial Tachycardia Market Overview


The paroxysmal atrial tachycardia market is expected to reach USD 10.7 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.5 % during the forecast period 2017-2023. Paroxysmal atrial tachycardia is irregular heartbeat and is a type of atrial arrhythmia where the episode of arrhythmia begins and ends abruptly. Paroxysmal atrial tachycardia (PAT) is also known as paroxysmal supraventricular tachycardia (PSVT). PAT increases heart rate from 60 to 100 beats per minute (bpm) to between 130 and 230 bpm with infants demonstrating heart rate greater than 220 bpm. PAT is the most common form of tachycardia in infants and children. Symptoms of PAT may include palpitations, lightheadedness, sweating, shortness of breath, chest pain and others. PAT is not usually a life-threatening disorder and the symptoms subside on their own. However, in rare cases, PAT may cause unconsciousness, congestive heart failure, cardiomyopathy and cardiac arrest. Having other heart issues such heart attacks or valve disease increase risk for PAT.


The cause of PAT are unknown but risk factors include alcohol, caffeine, nicotine, psychological stress, and Wolff-Parkinson-White syndrome. PAT occurs when electrical signals starting in the heart’s atria fire irregularly which affects the electrical signals transmitted from the sinoatrial node. This irregular beating prevents your heart from having enough time to fill with blood before pumping blood resulting in the body not receiving enough blood or oxygen. Women are at a higher risk for PAT than men.

Key Players in the Global Paroxysmal Atrial Tachycardia Market

Some of the key players profiled in the report are Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others.


Intended Audience



  • Global Paroxysmal Atrial Tachycardia manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


The market drivers for paroxysmal atrial tachycardia market are rise in demand due to growing older population, increasing screening, greater emphasis on cardiac treatment, urgency of the paroxysmal atrial tachycardia treatment, rise in risk factors and others. The market restraints are the complications such as risk of bleeding, infections, pain, especially during surgery, high cost of paroxysmal atrial tachycardia treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.


Segments

The paroxysmal atrial tachycardia market has been segmented on the basis of types, condition, diagnosis, drugs, surgery and end user.


Based on the types, the paroxysmal atrial tachycardia market has been segmented as AV nodal re-entrant tachycardia (AVNRT), AV reciprocating tachycardia (AVRT), and paroxysmal atrial tachycardia.


Based on the diagnosis, the paroxysmal atrial tachycardia market has been segmented as electrocardiogram (ECG), echocardiogram, blood tests, and electrophysiology study (EPS) and others.


Based on the treatment, the paroxysmal atrial tachycardia market has been segmented as calcium channel blockers, digoxin, beta-blockers, anti-arrhythmic medications, surgical ablation and others.


Based on the end user, the paroxysmal atrial tachycardia market has been segmented as hospitals and clinics, research and academics and others.


Figure 1: Global Paroxysmal Atrial Tachycardia Market by Treatment, 2016 (%) Global Paroxysmal Atrial Tachycardia Market


Regional Analysis
The Americas account for a significant market share owing to high expenditure on the health care especially in the U.S. and Canada. Additionally, the greater number of cardiac procedures due to greater healthcare penetration in the U.S. and Canada drives the paroxysmal atrial tachycardia market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is also adding fuel to the market growth. Moreover, the large share of cardiac procedures especially the cardiac surgery treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of paroxysmal atrial tachycardia market in the U.S. The high development of microsurgery field in developed regions such as the U.S. and Europe is a strong driver of the market.


Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry.


Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future paroxysmal atrial tachycardia market in the region. However the low expenditure on cardiac and eye care coupled with the lack of insurance penetration in the developing regions is a dent on the market.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa. The focus of the governments of poor countries on fulfilling basic healthcare relegates the paroxysmal atrial tachycardia market to the background which hampers the development of the market.


Research Methodology
Paroxysmal Atrial Tachycardia Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


The report for Paroxysmal Atrial Tachycardia Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.


 



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 10.7 billion
  • 2027: Significant Value
  •   CAGR   6.5 % (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Types, Condition, Diagnosis, Drugs, Surgery and End user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rise in demand due to growing older population
  • Increasing screening
  • Greater emphasis on cardiac treatment
  • Urgency of the paroxysmal atrial tachycardia treatment
  • Rise in risk factors and others


  • Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Paroxysmal Atrial Tachycardia Market, by Types

    6.1 Introduction

    6.2 AV nodal re-entrant tachycardia (AVNRT)

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 AV reciprocating tachycardia (AVRT)

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 Paroxysmal atrial tachycardia

    6.4.1 Market Estimates & Forecast, 2020-2027

    7. Global Paroxysmal Atrial Tachycardia Market, by Diagnosis

    7.1 Introduction

    7.2 Electrocardiogram (ECG)

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.3 Echocardiogram

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Blood tests

    7.4.1 Market Estimates & Forecast, 2020-2027

    7.5 Electrophysiology study (EPS)

    7.5.1 Market Estimates & Forecast, 2020-2027

    7.6 Others

    7.6.1 Market Estimates & Forecast, 2020-2027

    8. Global Paroxysmal Atrial Tachycardia Market, by Treatment

    8.1 Introduction

    8.2 Calcium channel blockers

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Digoxin

    8.3.1 Market Estimates & Forecast, 2020-2027

    8.4 Beta-blockers

    8.4.1 Market Estimates & Forecast, 2020-2027

    8.5 Anti-arrhythmic medications

    8.5.1 Market Estimates & Forecast, 2020-2027

    8.6 Surgical ablation

    8.6.1 Market Estimates & Forecast, 2020-2027

    8.7 Others

    8.7.1 Market Estimates & Forecast, 2020-2027

    9. Global Paroxysmal Atrial Tachycardia Market, by End-User

    9.1 Introduction

    9.2 Hospitals and Clinics

    9.2.1 Market Estimates & Forecast, 2020-2027

    9.3 Research and Academics

    9.3.1 Market Estimates & Forecast, 2020-2027

    9.4 Others

    9.4.1 Market Estimates & Forecast, 2020-2027

    10. Global Paroxysmal Atrial Tachycardia Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 UK

    10.3.1.4 Italy

    10.3.1.5 Spain

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    12. Company Profiles

    12.1 Abbott Laboratories

    12.1.1 Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 Key

    12.2 Reliant Pharmaceuticals C

    12.2.1 Overview

    12.2.2 Product Overview

    12.2.3 Financials

    12.2.4 Key Developments

    12.3 Novartis AG

    12.3.1 Overview

    12.3.2 Product Overview

    12.3.3 Financials

    12.3.4 Key Development

    12.4 AstraZeneca PLC

    12.4.1 Overview

    12.4.2 Product Overview

    12.4.3 Financials

    12.4.4 Key Development

    12.5 BIOTRONIK SE & Co. KG

    12.5.1 Overview

    12.5.2 Product Overview

    12.5.3 Financials

    12.5.4 Key Development

    12.6 Teva pharmaceutical industries

    12.6.1 Overview

    12.6.2 Product Overview

    12.6.3 Financials

    12.6.4 Key Development

    12.7 Boston Scientific Corporation

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Development

    12.8 Glenmark Pharmaceuticals

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Development

    12.9 Koninklijke Philips N.V.

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Development

    13. MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Paroxysmal Atrial Tachycardia Treatment Industry

    14. Appendix


    List of Tables

    TABLE 1 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES, 2020-2027 (USD MILLION)

    TABLE 2 AV NODAL RE-ENTRANT TACHYCARDIA (AVNRT) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 3 AV RECIPROCATING TACHYCARDIA (AVRT) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 4 PAROXYSMAL ATRIAL TACHYCARDIA FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 6 ELECTROCARDIOGRAM (ECG) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 7 ECHOCARDIOGRAM FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 8 BLOOD TESTS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 9 ELECTROPHYSIOLOGY STUDY (EPS) FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 10 OTHERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 11 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 12 CALCIUM CHANNEL BLOCKERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 13 DIGOXIN FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 14 BETA BLOCKERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 15 ANTI-ARRHYTHMIC MEDICATIONS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 16 SURGICAL ABLATION FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 17 OTHERS FOR PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 18 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 19 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 20 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2020-2027 (USD MILLION)

    TABLE 21 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 22 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 23 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 24 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET BY REGION 2020-2027 (USD MILLION

    TABLE 25 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 26 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2020-2027 (USD MILLION)

    TABLE 27 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 28 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 29 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 30 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET BY REGION 2020-2027 (USD MILLION)

    TABLE 31 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2020-2027 (USD MILLION)

    TABLE 32 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 33 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 34 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 35 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET BY REGION 2020-2027 (USD MILLION)

    TABLE 36 MIDDLE EAST & AFRICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 37 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2020-2027 (USD MILLION)

    TABLE 38 MIDDLE EAST & AFRICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 39 MIDDLE EAST & AFRICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 40 MIDDLE EAST & AFRICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 41 MIDDLE EAST & AFRICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET BY REGION 2020-2027 (USD MILLION

    List of Figures

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET DYNAMICS FOR GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET

    FIGURE 3 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MAKRET, BY SEGMENT, 2020

    FIGURE 4 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA SUCCESS MARKET, BY REGION

    FIGURE 5 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY TYPES 2020

    FIGURE 6 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY DIAGNOSIS 2020

    FIGURE 7 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY TREATMENT 2020

    FIGURE 8 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY END USER, 2020

    FIGURE 9 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, 2020

    FIGURE 10 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY REGION, 2020

    FIGURE 11 NORTH AMERICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY COUNTRY, 2020

    FIGURE 12 EUROPE PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY COUNTRY, 2020

    FIGURE 13 ASIA PACIFIC PAROXYSMAL ATRIAL TACHYCARDIA MARKET SHARE, BY COUNTRY, 2020

    FIGURE 14 MIDDLE EAST & AFRICA PAROXYSMAL ATRIAL TACHYCARDIA MARKET, BY REGION, 2020

    FIGURE 15 GLOBAL PAROXYSMAL ATRIAL TACHYCARDIA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 16 ABBOTT LABORATORIES: KEY FINANCIALS

    FIGURE 17 ABBOTT LABORATORIES: SEGMENTAL REVENUE

    FIGURE 18 ABBOTT LABORATORIES: GEOGRAPHICAL REVENUE

    FIGURE 19 RELIANT PHARMACEUTICALS: KEY FINANCIALS

    FIGURE 20 RELIANT PHARMACEUTICALS: SEGMENTAL REVENUE

    FIGURE 21 RELIANT PHARMACEUTICALS: GEOGRAPHICAL REVENUE

    FIGURE 22 GLAXOSMITHKLINE PLC: KEY FINANCIALS

    FIGURE 23 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

    FIGURE 24 GLAXOSMITHKLINE PLC: GEOGRAPHICAL REVENUE

    FIGURE 25 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS

    FIGURE 26 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE

    FIGURE 27 BOSTON SCIENTIFIC CORPORATION: GEOGRAPHICAL REVENUE

    FIGURE 28 NOVARTIS INTERNATIONAL AG: FINANCIAL REVENUE

    FIGURE 29 NOVARTIS INTERNATIONAL AG: SEGMENTAL REVENUE

    FIGURE 30 NOVARTIS INTERNATIONAL AG: GEOGRPAHICAL REVENUE